. 2021 Jul 6;54(4):402–411. doi: 10.1111/apt.16477

TABLE 4.

Summary of treatment‐emergent adverse events (TEAEs) and drug‐related TEAEs (safety analysis set)

TEAE	Tegoprazan						Placebo
	50 mg			100 mg			Placebo
	(n = 108)			(n = 108)			(n = 107)
	n	(%)	[F]	n	(%)	[F]	n	(%)	[F]
Most frequently reported TEAEs by system organ class and preferred term^a
Nervous system disorders	2	(1.9)	[2]	6	(5.6)	[6]	3	(2.8)	[5]
Headache	2	(1.9)	[2]	4	(3.7)	[4]	5	(4.7)	[5]
Infections and infestations	4	(3.7)	[4]	5	(4.6)	[5]	6	(5.6)	[6]
Nasopharyngitis	3	(2.8)	[3]	4	(3.7)	[4]	5	(4.7)	[5]
Most frequently reported drug‐related TEAEs by system organ class and preferred term^b
Gastrointestinal disorders	8	(7.4)	[13]	3	(2.8)	[3]	7	(6.5)	[8]
Nausea	3	(2.8)	[5]	1	(0.9)	[1]	2	(1.9)	[2]
Infections and infestations	1	(0.9)	[1]	2	(1.9)	[2]	3	(2.8)	[3]
Nasopharyngitis	1	(0.9)	[1]	2	(1.9)	[2]	3	(2.8)	[3]
Nervous system disorders	1	(0.9)	[1]	5	(4.6)	[5]	2	(1.9)	[3]
Headache	1	(0.9)	[1]	5	(4.6)	[5]	2	(1.9)	[3]

Abbreviations: [F], Frequency of TEAEs; SAEs, serious adverse events.

^{^a}

≥4%.

^{^b}

≥2%.